{"gao_id": "GAO-25-106775", "published": "2024-11-13T12:00:00Z", "released": "2024-11-13T07:00:00Z", "summary": "The Food and Drug Administration paused many drug manufacturer inspections during the COVID-19 pandemic. Inspections help ensure that the drugs Americans rely on are safe. Since resuming inspections, FDA has struggled to retain staff. From Nov. 2021 to June 2024, the vacancy rate among investigators who inspect foreign and domestic manufacturers jumped from 9% to 16%\u2014leading to fewer inspections. FDA said concerns with travel, pay...", "title": "Drug Safety: FDA Should Implement Strategies to Retain Its Inspection Workforce", "topics": ["pandemics", "Federal hiring", "Drugs", "Labor force", "Drug safety", "Agency evaluations", "Compliance oversight", "Manufacturing", "Government Operations", "Prescription drugs", "Employee retention"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-25-106775", "versions": [{"title": "View Full Report Online", "url": "https://files.gao.gov/reports/GAO-25-106775/index.html"}, {"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-25-106775-highlights.pdf"}, {"title": "Full Report (67 pages)", "url": "https://www.gao.gov/assets/gao-25-106775.pdf"}]}